查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1980650

韓特氏症治療市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類的洞察，2026-2034 年預測

Hunter Syndrome Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 130 Pages | 商品交期: 請詢問到貨日

價格

韓特氏症治療市場的成長要素

全球韓特氏症治療市場預計到 2025 年將達到 10.5 億美元，到 2026 年將成長到 11.2 億美元，到 2034 年將達到 18.1 億美元，2026 年至 2034 年的複合年成長率為 6.20%。

由於健全的保險報銷制度、高診斷率以及主要生物製藥公司的存在，預計到 2025 年，北美將引領全球市場，佔據 50.84% 的市場佔有率。

韓特氏症（黏多醣症II型，MPS II）是一種罕見的遺傳性溶小體貯積症，由體內無法分解黏多醣體引起。此病主要影響男性，如不治療，可顯著縮短平均壽命。針對神經系統併發症的研究、開發和臨床試驗投入的增加，正在推動市場擴張。

市場趨勢

加大對罕見疾病研究和開發的投入

影響市場的關鍵趨勢之一是孤兒藥研發投入的增加。多家生技公司正處於臨床階段，開發包括基因療法和腦滲透性酶療法在內的先進治療方法。

以下公司：

  • ArmaGen
  • REGENXBIO Inc.
  • Denali Therapeutics

這些公司正積極推動其在研候選藥物的研發。

罕見疾病藥物通常享有監管方面的優勢，例如快速核准和市場獨佔權。與糖尿病和冠狀動脈疾病等傳統慢性病相比，孤兒藥的核准所需療效研究小規模，這使得該領域更具創新吸引力。

市場促進因素

1. 未滿足的需求

目前，市場上只有兩種已通過核准的治療方法：

  • 埃拉普拉澤
  • 亨特茲

艾拉普拉西在全球範圍內仍是一種主要的治療方法，但其高昂的價格使得許多新興市場的患者難以負擔。亨特澤在一些國家已獲核准，但價格仍然昂貴。

此外，目前的酵素替代療法（ERT）無法穿過血腦障壁，導致神經系統症狀無法治療。約三分之二的患者會出現嚴重的神經系統併發症，因此亟需能夠治療中樞神經系統病變的下一代治療方法。

2. 一個強大的管道

根據遺傳和罕見疾病資訊中心（GARD）的數據，美國約有7000種罕見疾病，影響2500萬至3000萬人。這加速了對MPS II等罕見疾病的研究和發展。

隨著產品線的擴張和臨床試驗活動的活性化，預計到 2034 年，市場將顯著成長。

市場限制因素

新興市場醫療成本高且醫療服務可近性低

酵素替代療法的主要阻礙因素仍然是高成本。在許多新興國家，保險報銷有限，大眾認知度低，治療機會仍不足。因此，大多數確診患者未能得到治療。

細分分析

按類型治療

市場區隔按以下步驟進行：

  • 酵素替代療法（ERT）
  • 其他（基因療法、造血幹細胞移植（HSCT）、新興治療方法）

ERT（酵素替代療法）佔據市場主導地位，預計到 2026 年將佔據 93.38% 的市場佔有率。 Elaprase 和 Hunterase 均為 ERT，並保持在該領域的主導地位。

由於基因治療和造血幹細胞移植（HSCT）的進步，「其他」細分市場預計將以更高的複合年成長率成長。

透過行政途徑

  • 靜脈
  • 腦室內腔（ICV）/鞘內腔

靜脈注射領域，主要由 Elaprace 的靜脈注射途徑推動，預計到 2026 年將佔市場佔有率的 97.46%。

最終用戶

  • 醫院
  • 專科診所
  • 其他

由於靜脈注射 ERT 需要專門的醫療監督，預計到 2026 年，醫院將佔市場佔有率的 61.70%。

區域分析

北美洲

預計北美市場在 2025 年將達到 5.4 億美元，在 2026 年將達到 5.7 億美元。該地區憑藉高診斷率、健全的報銷機制和活躍的臨床開發平臺，正在推動市場發展。

預計到 2026 年，光是美國市場規模就將達到 5.3 億美元。

亞太地區

預計亞太地區在預測期內將維持較高的複合年成長率。日本受惠於漢特茲產品的普及，而中國和印度的市場滲透率較低。

到2026年：

  • 日本：1億美元
  • 中國：3000萬美元
  • 印度：7000萬美元

歐洲

在歐洲，由於對罕見疾病的支持性政策和先進治療方法的廣泛應用，預計會穩定成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇

第4章：主要考慮因素

  • 管道分析
  • 主要行業趨勢
  • 監理情勢：依主要區域分類
  • 韓特氏症新興治療方法概述
  • 還款狀況：依主要地區分類

第5章：2021-2034年全球韓特氏症治療市場分析、洞察與預測

  • 主要發現與總結
  • 市場分析、洞察與預測：按治療方式分類
    • 酵素替代療法（ERT）
    • 其他
  • 市場分析、洞察與預測：按給藥途徑
    • 靜脈
    • 腦室內腔/脊髓腔
  • 市場分析、洞察與預測：按最終用戶分類
    • 醫院
    • 專科診所
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第6章：北美韓特氏症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲韓特氏症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他歐洲國家

第8章：亞太地區韓特氏症治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 韓國
    • 其他亞太國家

第9章：韓特氏症治療市場分析、洞察及2021-2034年世界其他地區預測

第10章 競爭分析

  • 主要行業趨勢
  • 全球市佔率分析（2017）
  • 競爭對手儀錶板
  • 主要企業比較分析
  • 公司簡介
    • Shire（Takeda Pharmaceutical Company Limited）
    • Denali Therapeutics
    • ArmaGen
    • Inventiva
    • Green Cross Corp.（GC Pharma）
    • CANbridge Life Sciences Ltd.
    • JCR Pharmaceuticals Co., Ltd.
    • REGENXBIO Inc.
    • Sangamo Therapeutics

第11章 策略建議

Product Code: FBI102536

Growth Factors of Hunter syndrome treatment Market

The global Hunter syndrome treatment market was valued at USD 1.05 billion in 2025 and is projected to grow to USD 1.12 billion in 2026, reaching USD 1.81 billion by 2034, registering a CAGR of 6.20% during 2026-2034.

North America dominated the global market with a 50.84% market share in 2025, supported by strong reimbursement frameworks, higher diagnosis rates, and the presence of major biopharmaceutical players.

Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II), is a rare inherited lysosomal storage disorder caused by the body's inability to break down mucopolysaccharides. The disease primarily affects males and can significantly shorten life expectancy if untreated. Increasing R&D investments and clinical trials targeting neurological complications are shaping market expansion.

Market Trends

Rising R&D Investments in Rare Diseases

A significant trend influencing the market is the growing investment in orphan drug research. Several clinical-stage biotechnology companies are developing advanced therapies, including gene therapies and brain-penetrant enzyme treatments.

Companies such as:

  • ArmaGen
  • REGENXBIO Inc.
  • Denali Therapeutics

are actively advancing pipeline candidates.

Rare diseases often receive regulatory advantages such as faster approvals and market exclusivity. Compared to traditional chronic diseases like diabetes or coronary artery disease, orphan drug approvals require smaller outcome studies, making the segment attractive for innovation.

Market Drivers

1. Unmet Clinical Needs

Currently, only two approved therapies dominate the market:

  • Elaprase
  • Hunterase

Elaprase remains the primary treatment globally but is expensive and inaccessible to many patients in emerging economies. Hunterase is approved in select countries but also remains costly.

Additionally, current enzyme replacement therapies (ERTs) cannot cross the blood-brain barrier, leaving neurological symptoms untreated. Approximately two-thirds of patients suffer severe neurological complications, creating demand for next-generation therapies capable of addressing central nervous system involvement.

2. Strong Pipeline Presence

According to the Genetic and Rare Diseases Information Center (GARD), nearly 7,000 rare diseases affect 25-30 million individuals in the U.S. This has accelerated R&D in rare disorders like MPS II.

Pipeline expansion and growing clinical trial activity are expected to drive substantial market growth through 2034.

Market Restraints

High Treatment Costs & Low Access in Emerging Markets

The major restraint remains the high cost of enzyme replacement therapies. In many emerging countries, reimbursement support is limited, awareness is low, and treatment access remains inadequate. As a result, a large proportion of diagnosed patients remain untreated.

Segmentation Analysis

By Treatment

The market is segmented into:

  • Enzyme Replacement Therapy (ERT)
  • Others (Gene therapy, HSCT, emerging modalities)

ERT dominated the market and is projected to account for 93.38% share in 2026. Both Elaprase and Hunterase are ERTs, maintaining segment leadership.

The "Others" segment is expected to grow at a higher CAGR due to advancements in gene therapy and hematopoietic stem cell transplant (HSCT).

By Route of Administration

  • Intravenous
  • Intracerebroventricular (ICV)/Intrathecal

The intravenous segment is expected to hold 97.46% market share in 2026, primarily due to Elaprase's intravenous administration route.

By End User

  • Hospitals
  • Specialty Clinics
  • Others

Hospitals are projected to hold 61.70% market share in 2026, as intravenous ERT administration requires specialized medical supervision.

Regional Analysis

North America

North America recorded USD 0.54 billion in 2025 and USD 0.57 billion in 2026. The region led the market due to high diagnosis rates, strong reimbursement systems, and active clinical pipelines.

The U.S. market alone is expected to reach USD 0.53 billion by 2026.

Asia Pacific

Asia Pacific is projected to register a higher CAGR during the forecast period. Japan benefits from Hunterase availability, while China and India represent underpenetrated markets.

By 2026:

  • Japan: USD 0.10 billion
  • China: USD 0.03 billion
  • India: USD 0.07 billion

Europe

Europe is expected to witness steady growth due to favorable rare disease policies and increasing adoption of advanced therapies.

Competitive Landscape

The market remains largely monopolistic, dominated by:

  • Shire (now part of Takeda Pharmaceutical Company Limited)

Elaprase's strong clinical performance and global approval maintain Takeda's leading position.

Other key companies include:

  • JCR Pharmaceuticals Co., Ltd.
  • Green Cross Corp.
  • CANbridge Life Sciences Ltd.
  • Sangamo Therapeutics
  • Inventiva

Key Industry Developments

  • July 2021 - Denali Therapeutics announced positive clinical data for ETV:IDS, a brain-penetrant enzyme therapy.
  • May 2021 - Inventiva presented updates on oral small molecule therapies for MPS disorders.
  • March 2018 - Shire partnered with NanoMedSyn to explore advanced enzyme replacement therapies.

Conclusion

The global Hunter syndrome treatment market is poised for steady growth from USD 1.05 billion in 2025 to USD 1.81 billion by 2034, driven by increasing R&D investments, unmet neurological treatment needs, and expanding orphan drug pipelines. While high therapy costs and limited access in emerging economies remain major restraints, innovation in gene therapy and brain-penetrant treatments is expected to transform the competitive landscape.

Segmentation By Treatment

  • Enzyme Replacement Therapy (ERT)
  • Others

By Route of Administration

  • Intravenous
  • Intracerebroventricular (ICV)/ Intrathecal

By End User

  • Hospitals
  • Specialty Clinics
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
  • Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
  • Rest of the World

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Pipeline Analysis
  • 4.2. Key Industry Developments
  • 4.3. Regulatory Scenario by Key Regions
  • 4.4. Overview of Emerging Treatments for Hunter Syndrome
  • 4.5. Reimbursement Scenario by Key Regions

5. Global Hunter Syndrome Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Treatment
    • 5.2.1. Enzyme Replacement Therapy (ERT)
    • 5.2.2. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Intravenous
    • 5.3.2. Intracerebroventricular (ICV)/ Intrathecal
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Hospitals
    • 5.4.2. Specialty Clinics
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Rest of the World

6. North America Hunter Syndrome Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Treatment
    • 6.2.1. Enzyme Replacement Therapy (ERT)
    • 6.2.2. Others
  • 6.3. Market Analysis - By Route of Administration
    • 6.3.1. Intravenous
    • 6.3.2. Intracerebroventricular (ICV)/ Intrathecal
  • 6.4. Market Analysis - By End User
    • 6.4.1. Hospitals
    • 6.4.2. Specialty Clinics
    • 6.4.3. Others
  • 6.5. Market Analysis - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Hunter Syndrome Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Treatment
    • 7.2.1. Enzyme Replacement Therapy (ERT)
    • 7.2.2. Others
  • 7.3. Market Analysis - By Route of Administration
    • 7.3.1. Intravenous
    • 7.3.2. Intracerebroventricular (ICV)/ Intrathecal
  • 7.4. Market Analysis - By End User
    • 7.4.1. Hospitals
    • 7.4.2. Specialty Clinics
    • 7.4.3. Others
  • 7.5. Market Analysis - By Country/ sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Rest of Europe

8. Asia pacific Hunter Syndrome Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Treatment
    • 8.2.1. Enzyme Replacement Therapy (ERT)
    • 8.2.2. Others
  • 8.3. Market Analysis - By Route of Administration
    • 8.3.1. Intravenous
    • 8.3.2. Intracerebroventricular (ICV)/ Intrathecal
  • 8.4. Market Analysis - By End User
    • 8.4.1. Hospitals
    • 8.4.2. Specialty Clinics
    • 8.4.3. Others
  • 8.5. Market Analysis - By Country/ sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. South Korea
    • 8.5.5. Rest of Asia Pacific

9. Rest of the World Hunter Syndrome Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Treatment
    • 9.2.1. Enzyme Replacement Therapy (ERT)
    • 9.2.2. Others
  • 9.3. Market Analysis - By Route of Administration
    • 9.3.1. Intravenous
    • 9.3.2. Intracerebroventricular (ICV)/ Intrathecal
  • 9.4. Market Analysis - By End User
    • 9.4.1. Hospitals
    • 9.4.2. Specialty Clinics
    • 9.4.3. Others

10. Competitive Analysis

  • 10.1. Key Industry Developments
  • 10.2. Global Market Share Analysis (2017)
  • 10.3. Competition Dashboard
  • 10.4. Comparative Analysis - Major Players
  • 10.5. Company Profiles
    • 10.5.1. Shire (Takeda Pharmaceutical Company Limited)
      • 10.5.1.1. Overview,
      • 10.5.1.2. Products & services,
      • 10.5.1.3. SWOT analysis,
      • 10.5.1.4. Recent developments,
      • 10.5.1.5. strategies,
      • 10.5.1.6. financials (based on availability)
    • 10.5.2. Denali Therapeutics
      • 10.5.2.1. Overview,
      • 10.5.2.2. Products & services,
      • 10.5.2.3. SWOT analysis,
      • 10.5.2.4. Recent developments,
      • 10.5.2.5. strategies,
      • 10.5.2.6. financials (based on availability)
    • 10.5.3. ArmaGen
      • 10.5.3.1. Overview,
      • 10.5.3.2. Products & services,
      • 10.5.3.3. SWOT analysis,
      • 10.5.3.4. Recent developments,
      • 10.5.3.5. strategies,
      • 10.5.3.6. financials (based on availability)
    • 10.5.4. Inventiva
      • 10.5.4.1. Overview,
      • 10.5.4.2. Products & services,
      • 10.5.4.3. SWOT analysis,
      • 10.5.4.4. Recent developments,
      • 10.5.4.5. strategies,
      • 10.5.4.6. financials (based on availability)
    • 10.5.5. Green Cross Corp. (GC Pharma)
      • 10.5.5.1. Overview,
      • 10.5.5.2. Products & services,
      • 10.5.5.3. SWOT analysis,
      • 10.5.5.4. Recent developments,
      • 10.5.5.5. strategies,
      • 10.5.5.6. financials (based on availability)
    • 10.5.6. CANbridge Life Sciences Ltd.
      • 10.5.6.1. Overview,
      • 10.5.6.2. Products & services,
      • 10.5.6.3. SWOT analysis,
      • 10.5.6.4. Recent developments,
      • 10.5.6.5. strategies,
      • 10.5.6.6. financials (based on availability)
    • 10.5.7. JCR Pharmaceuticals Co., Ltd.
      • 10.5.7.1. Overview,
      • 10.5.7.2. Products & services,
      • 10.5.7.3. SWOT analysis,
      • 10.5.7.4. Recent developments,
      • 10.5.7.5. strategies,
      • 10.5.7.6. financials (based on availability)
    • 10.5.8. REGENXBIO Inc.
      • 10.5.8.1. Overview,
      • 10.5.8.2. Products & services,
      • 10.5.8.3. SWOT analysis,
      • 10.5.8.4. Recent developments,
      • 10.5.8.5. strategies,
      • 10.5.8.6. financials (based on availability)
    • 10.5.9. Sangamo Therapeutics
      • 10.5.9.1. Overview,
      • 10.5.9.2. Products & services,
      • 10.5.9.3. SWOT analysis,
      • 10.5.9.4. Recent developments,
      • 10.5.9.5. strategies,
      • 10.5.9.6. financials (based on availability)

11. Strategic Recommendation

List of Tables

  • Table 1: Global Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 2: Global Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
  • Table 4: Global Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 6: North America Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
  • Table 8: North America Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 10: Europe Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 11: Europe Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
  • Table 12: Europe Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 14: Asia Pacific Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 15: Asia Pacific Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
  • Table 16: Asia Pacific Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 18: Latin America Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 19: Latin America Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
  • Table 20: Latin America Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 22: Middle East & Africa Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 23: Middle East & Africa Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2021-2034
  • Table 24: Middle East & Africa Hunter Syndrome Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Hunter Syndrome Treatment Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
  • Figure 2: Global Hunter Syndrome Treatment Market Value Share (%), by Treatment, 2025 & 2034
  • Figure 3: Global Hunter Syndrome Treatment Market Forecast (US$ Mn), by Enzyme Replacement Therapy (ERT), 2021-2034
  • Figure 4: Global Hunter Syndrome Treatment Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 5: Global Hunter Syndrome Treatment Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 6: Global Hunter Syndrome Treatment Market Forecast (US$ Mn), by Intravenous, 2021-2034
  • Figure 7: Global Hunter Syndrome Treatment Market Forecast (US$ Mn), by Intracerebroventricular (ICV)/ Intrathecal, 2021-2034
  • Figure 8: Global Hunter Syndrome Treatment Market Value Share (%), by End-user, 2025 & 2034
  • Figure 9: Global Hunter Syndrome Treatment Market Forecast (US$ Mn), by Hospitals, 2021-2034
  • Figure 10: Global Hunter Syndrome Treatment Market Forecast (US$ Mn), by Specialty Clinics, 2021-2034
  • Figure 11: Global Hunter Syndrome Treatment Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 12: Global Hunter Syndrome Treatment Market Value (US$ Mn), by Region, 2025 & 2034
  • Figure 13: North America Hunter Syndrome Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 14: North America Hunter Syndrome Treatment Market Value Share (%), by Treatment, 2025
  • Figure 15: North America Hunter Syndrome Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
  • Figure 16: North America Hunter Syndrome Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 17: North America Hunter Syndrome Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
  • Figure 18: North America Hunter Syndrome Treatment Market Value Share (%), by End-user, 2025
  • Figure 19: North America Hunter Syndrome Treatment Market Value (US$ Mn), By Country, 2025 & 2034
  • Figure 20: North America Hunter Syndrome Treatment Market Value Share (%), By Country, 2025
  • Figure 21: Europe Hunter Syndrome Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 22: Europe Hunter Syndrome Treatment Market Value Share (%), by Treatment, 2025
  • Figure 23: Europe Hunter Syndrome Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
  • Figure 24: Europe Hunter Syndrome Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 25: Europe Hunter Syndrome Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
  • Figure 26: Europe Hunter Syndrome Treatment Market Value Share (%), by End-user, 2025
  • Figure 27: Europe Hunter Syndrome Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 28: Europe Hunter Syndrome Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 29: Asia Pacific Hunter Syndrome Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 30: Asia Pacific Hunter Syndrome Treatment Market Value Share (%), by Treatment, 2025
  • Figure 31: Asia Pacific Hunter Syndrome Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Hunter Syndrome Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Hunter Syndrome Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
  • Figure 34: Asia Pacific Hunter Syndrome Treatment Market Value Share (%), by End-user, 2025
  • Figure 35: Asia Pacific Hunter Syndrome Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Hunter Syndrome Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Hunter Syndrome Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 38: Latin America Hunter Syndrome Treatment Market Value Share (%), by Treatment, 2025
  • Figure 39: Latin America Hunter Syndrome Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
  • Figure 40: Latin America Hunter Syndrome Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 41: Latin America Hunter Syndrome Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
  • Figure 42: Latin America Hunter Syndrome Treatment Market Value Share (%), by End-user, 2025
  • Figure 43: Latin America Hunter Syndrome Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 44: Latin America Hunter Syndrome Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 45: Middle East & Africa Hunter Syndrome Treatment Market Value (US$ Mn), by Treatment, 2025 & 2034
  • Figure 46: Middle East & Africa Hunter Syndrome Treatment Market Value Share (%), by Treatment, 2025
  • Figure 47: Middle East & Africa Hunter Syndrome Treatment Market Value (US$ Mn), by Route of Administration, 2025 & 2034
  • Figure 48: Middle East & Africa Hunter Syndrome Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 49: Middle East & Africa Hunter Syndrome Treatment Market Value (US$ Mn), by End-user, 2025 & 2034
  • Figure 50: Middle East & Africa Hunter Syndrome Treatment Market Value Share (%), by End-user, 2025
  • Figure 51: Middle East & Africa Hunter Syndrome Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 52: Middle East & Africa Hunter Syndrome Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 53: Global Hunter Syndrome Treatment Market Share (%), By Company, 2025